TY - JOUR T1 - Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19) JF - medRxiv DO - 10.1101/2020.02.28.20029272 SP - 2020.02.28.20029272 AU - Hiroshi Nishiura AU - Hitoshi Oshitani AU - Tetsuro Kobayashi AU - Tomoya Saito AU - Tomimasa Sunagawa AU - Tamano Matsui AU - Takaji Wakita AU - MHLW COVID-19 Response Team AU - Motoi Suzuki Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/03/2020.02.28.20029272.abstract N2 - Commissioned by the Minister of the Ministry of Health, Labour, and Welfare of Japan, we collected secondary transmission data with the aim of identifying high risk transmission settings. We show that closed environments contribute to secondary transmission of COVID-19 and promote superspreading events. Closed environments are consistent with large-scale COVID-19 transmission events such as that of the ski chalet-associated cluster in France and the church- and hospital-associated clusters in South Korea. Our findings are also consistent with the declining incidence of COVID-19 cases in China, as gathering in closed environments was prohibited in the wake of the rapid spread of the disease. Reduction of unnecessary close contact in closed environments may help prevent large case clusters and superspreading events.Competing Interest StatementThe authors have declared no competing interest.Funding StatementH.N. received funding from the Japan Agency for Medical Research and Development (AMED) [grant number: JP18fk0108050]; the Japan Society for the Promotion of Science (JSPS) KAKENHI [grant numbers, H.N.: 17H04701, 17H05808, 18H04895 and 19H01074], the Inamori Foundation, and the Japan Science and Technology Agency (JST) CREST program [grant number: JPMJCR1413].Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized dataset will be provided by the corresponding author upon request. ER -